0001157523-17-001590.txt : 20170516 0001157523-17-001590.hdr.sgml : 20170516 20170516163049 ACCESSION NUMBER: 0001157523-17-001590 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170516 FILED AS OF DATE: 20170516 DATE AS OF CHANGE: 20170516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectis S.A. CENTRAL INDEX KEY: 0001627281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36891 FILM NUMBER: 17848988 BUSINESS ADDRESS: STREET 1: 8 RUE DE LA CROIX JARRY CITY: PARIS, LLE-DE-FRANCE STATE: I0 ZIP: 75013 BUSINESS PHONE: 33181691600 MAIL ADDRESS: STREET 1: 8 RUE DE LA CROIX JARRY CITY: PARIS, LLE-DE-FRANCE STATE: I0 ZIP: 75013 6-K 1 a51560624.htm CELLECTIS S.A. 6-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934


Date of Report: May 16, 2017
Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞

EXHIBIT INDEX

Exhibit

 

Title

99.1

Press release, dated May 16, 2017.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLECTIS S.A.

(Registrant)

 

May 16, 2017

By:

/s/     André Choulika

André Choulika

Chief Executive Officer

3

EX-99.1 2 a51560624_ex991.htm EXHIBIT 99.1

Exhibit 99.1

Calyxt Launches U.S. Field Trials with University of Minnesota for Powdery Mildew-Resistant Spring Wheat Variety

Wheat Marks Calyxt’s Fourth Gene Edited Crop to Undergo Trials

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--May 16, 2017--Calyxt, Inc., a Minnesota-based company developing healthier specialty food ingredients to benefit both consumers and farmers, today announced that the Company, under a service agreement with the University of Minnesota, has launched field trials in the U.S. for its gene edited powdery mildew-resistant spring wheat variety.

Under the agreement, the University of Minnesota has planted 1.7 kilograms of seeds at the University’s St. Paul and Crookston research stations. Developed using Calyxt’s proprietary TALEN® technology, the wheat is resistant to powdery mildew, a fungus that spreads widely throughout the world and is responsible for major grain and yield losses.

“As Calyxt is dedicated to bringing crops to market with healthier characteristics for consumers and growers, working with the University of Minnesota to plant the powdery mildew-resistant wheat brings us one step closer to making the goal a reality and allows us to see how the wheat will look under field conditions,” said Federico Tripodi, Calyxt CEO. “Through altering one native gene in the crop, we are able to increase the productivity and profitability of farmers. With over 680 million metric tons of wheat that’s produced annually globally, Calyxt is well-positioned to incorporate the mildew resistance trait into geographically suitable wheat varieties and commercialize this product in the near future.”

In 2016, Calyxt received notice from the USDA’s Animal and Plant Health Inspection Service that the Company’s powdery mildew-resistant wheat variety is non-regulated, as no foreign DNA is contained in this powdery mildew-resistant spring wheat variety.

About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. By combining its leading gene-editing technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance, for farmers. Calyxt is located in Minneapolis-St. Paul, Minn., and is a wholly owned subsidiary of Cellectis.

For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.

Talking about gene editing? We do it.
TALEN® is a registered trademark owned by the Cellectis Group.

CONTACT:
For Calyxt
Media:
Jennifer Moore, 917-580-1088
VP Communications
media@calyxt.com
or
KCSA Strategic Communications
Caitlin Kasunich / Nick Opich
212-896-1241 / 212-896-1206
ckasunich@kcsa.com / nopich@kcsa.com
or
Investor Relations:
Simon Harnest, 646-385-9008
VP Corporate Strategy and Finance
simon.harnest@cellectis.com